ResearchMoz

Type 2 Diabetes - Pipeline Review, H1 2014

Global Markets Direct
Published Date » 2014-02-28
No. Of Pages » 1052
 Global Markets Direct’s, ‘Type 2 Diabetes - Pipeline Review, H1 2014’, provides an overview of the Type 2 Diabetes’s therapeutic pipeline. 
   
 This report provides comprehensive information on the therapeutic development for Type 2 Diabetes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects. 
   
 Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000...
Table of Content

Introduction
Type 2 Diabetes Overview
Therapeutics Development
Type 2 Diabetes - Therapeutics under Development by Companies
Type 2 Diabetes - Therapeutics under Investigation by Universities/Institutes
Type 2 Diabetes - Pipeline Products Glance
Type 2 Diabetes - Products under Development by Companies
Type 2 Diabetes - Products under Investigation by Universities/Institutes
Type 2 Diabetes - Companies Involved in Therapeutics Development
Type 2 Diabetes - Therapeutics Assessment
Drug Profiles
Type 2 Diabetes - Recent Pipeline Updates
Type 2 Diabetes - Dormant Projects
Type 2 Diabetes - Discontinued Products
Type 2 Diabetes - Product Development Milestones

Appendix

List of Tables


Number of Products under Development for Type 2 Diabetes, H1 2014
Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Development by Companies, H1 2014 (Contd..1)
Number of Products under Development by Companies, H1 2014 (Contd..2)
Number of Products under Development by Companies, H1 2014 (Contd..3)
Number of Products under Development by Companies, H1 2014 (Contd..4)
Number of Products under Development by Companies, H1 2014 (Contd..5)
Number of Products under Development by Companies, H1 2014 (Contd..6)
Number of Products under Development by Companies, H1 2014 (Contd..7)
Number of Products under Development by Companies, H1 2014 (Contd..8)
Number of Products under Development by Companies, H1 2014 (Contd..9)
Number of Products under Development by Companies, H1 2014 (Contd..10)
Number of Products under Development by Companies, H1 2014 (Contd..11)
Number of Products under Development by Companies, H1 2014 (Contd..12)
Number of Products under Development by Companies, H1 2014 (Contd..13)
Number of Products under Investigation by Universities/Institutes, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Development, H1 2014
Comparative Analysis by Unknown Stage Development, H1 2014
Products under Development by Companies, H1 2014
Products under Development by Companies, H1 2014 (Contd..1)
Products under Development by Companies, H1 2014 (Contd..2)
Products under Development by Companies, H1 2014 (Contd..3)
Products under Development by Companies, H1 2014 (Contd..4)
Products under Development by Companies, H1 2014 (Contd..5)
Products under Development by Companies, H1 2014 (Contd..6)
Products under Development by Companies, H1 2014 (Contd..7)
Products under Development by Companies, H1 2014 (Contd..8)
Products under Development by Companies, H1 2014 (Contd..9)
Products under Development by Companies, H1 2014 (Contd..10)
Products under Development by Companies, H1 2014 (Contd..11)
Products under Development by Companies, H1 2014 (Contd..12)
Products under Development by Companies, H1 2014 (Contd..13)
Products under Development by Companies, H1 2014 (Contd..14)
Products under Development by Companies, H1 2014 (Contd..15)
Products under Development by Companies, H1 2014 (Contd..16)
Products under Development by Companies, H1 2014 (Contd..17)
Products under Development by Companies, H1 2014 (Contd..18)
Products under Development by Companies, H1 2014 (Contd..19)
Products under Development by Companies, H1 2014 (Contd..20)
Products under Development by Companies, H1 2014 (Contd..21)
Products under Development by Companies, H1 2014 (Contd..22)
Products under Development by Companies, H1 2014 (Contd..23)
Products under Development by Companies, H1 2014 (Contd..24)
Products under Development by Companies, H1 2014 (Contd..25)
Products under Development by Companies, H1 2014 (Contd..26)
Products under Development by Companies, H1 2014 (Contd..27)
Products under Investigation by Universities/Institutes, H1 2014
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1)
Type 2 Diabetes - Pipeline by Bristol-Myers Squibb Company, H1 2014
Type 2 Diabetes - Pipeline by Johnson & Johnson, H1 2014
Type 2 Diabetes - Pipeline by Boehringer Ingelheim GmbH, H1 2014
Type 2 Diabetes - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014
Type 2 Diabetes - Pipeline by Shionogi & Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Amgen Inc., H1 2014
Type 2 Diabetes - Pipeline by Sanofi, H1 2014
Type 2 Diabetes - Pipeline by AstraZeneca PLC, H1 2014
Type 2 Diabetes - Pipeline by Eli Lilly and Company, H1 2014
Type 2 Diabetes - Pipeline by GlaxoSmithKline plc, H1 2014
Type 2 Diabetes - Pipeline by MedImmune, LLC, H1 2014
Type 2 Diabetes - Pipeline by Isis Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Gilead Sciences, Inc., H1 2014
Type 2 Diabetes - Pipeline by Daiichi Sankyo Company, Limited, H1 2014
Type 2 Diabetes - Pipeline by Merck & Co., Inc., H1 2014
Type 2 Diabetes - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Euroscreen S.A., H1 2014
Type 2 Diabetes - Pipeline by Novo Nordisk A/S, H1 2014
Type 2 Diabetes - Pipeline by Generex Biotechnology Corporation, H1 2014
Type 2 Diabetes - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014
Type 2 Diabetes - Pipeline by FibroGen, Inc., H1 2014
Type 2 Diabetes - Pipeline by Ipsen S.A., H1 2014
Type 2 Diabetes - Pipeline by Piramal Enterprises Limited, H1 2014
Type 2 Diabetes - Pipeline by Neurocrine Biosciences, Inc., H1 2014
Type 2 Diabetes - Pipeline by Teijin Pharma Limited, H1 2014
Type 2 Diabetes - Pipeline by Novartis AG, H1 2014
Type 2 Diabetes - Pipeline by Astellas Pharma Inc., H1 2014
Type 2 Diabetes - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Forest Laboratories, Inc., H1 2014
Type 2 Diabetes - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2014
Type 2 Diabetes - Pipeline by Japan Tobacco Inc., H1 2014
Type 2 Diabetes - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Les Laboratoires Servier SAS, H1 2014
Type 2 Diabetes - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014
Type 2 Diabetes - Pipeline by Pfizer Inc., H1 2014
Type 2 Diabetes - Pipeline by Ranbaxy Laboratories Limited, H1 2014
Type 2 Diabetes - Pipeline by Zydus Cadila Healthcare Limited, H1 2014
Type 2 Diabetes - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2014
Type 2 Diabetes - Pipeline by Biodel Inc., H1 2014
Type 2 Diabetes - Pipeline by Bayer AG, H1 2014
Type 2 Diabetes - Pipeline by OPKO Health, Inc., H1 2014
Type 2 Diabetes - Pipeline by MannKind Corporation, H1 2014
Type 2 Diabetes - Pipeline by Halozyme Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Toray Industries, Inc., H1 2014
Type 2 Diabetes - Pipeline by Merck KGaA, H1 2014
Type 2 Diabetes - Pipeline by Alchemia Limited, H1 2014
Type 2 Diabetes - Pipeline by Addex Therapeutics, H1 2014
Type 2 Diabetes - Pipeline by Evotec AG, H1 2014
Type 2 Diabetes - Pipeline by AlbireoPharma, H1 2014
Type 2 Diabetes - Pipeline by GW Pharmaceuticals plc, H1 2014
Type 2 Diabetes - Pipeline by Harbor Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Enzo Biochem, Inc., H1 2014
Type 2 Diabetes - Pipeline by Genfit SA, H1 2014
Type 2 Diabetes - Pipeline by Ligand Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Mesoblast Limited, H1 2014
Type 2 Diabetes - Pipeline by Oramed Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H1 2014
Type 2 Diabetes - Pipeline by ConjuChem Biotechnologies Inc., H1 2014
Type 2 Diabetes - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Arena Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Flamel Technologies S.A., H1 2014
Type 2 Diabetes - Pipeline by CSL Limited, H1 2014
Type 2 Diabetes - Pipeline by ProteoTech, Inc., H1 2014
Type 2 Diabetes - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Yuhan Corporation, H1 2014
Type 2 Diabetes - Pipeline by XOMA Corporation, H1 2014
Type 2 Diabetes - Pipeline by Immuron Limited, H1 2014
Type 2 Diabetes - Pipeline by IPCA Laboratories Limited, H1 2014
Type 2 Diabetes - Pipeline by Xenetic Biosciences plc, H1 2014
Type 2 Diabetes - Pipeline by Handok Inc., H1 2014
Type 2 Diabetes - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by LG Life Sciences, Ltd., H1 2014
Type 2 Diabetes - Pipeline by Transition Therapeutics Inc., H1 2014
Type 2 Diabetes - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Uni-Bio Science Group Ltd., H1 2014
Type 2 Diabetes - Pipeline by Panacea Biotec Limited, H1 2014
Type 2 Diabetes - Pipeline by Summit Corporation plc, H1 2014
Type 2 Diabetes - Pipeline by Phynova Group Ltd, H1 2014
Type 2 Diabetes - Pipeline by Genovate Biotechnology Co., LTD., H1 2014
Type 2 Diabetes - Pipeline by DiaMedica Inc., H1 2014
Type 2 Diabetes - Pipeline by NeuroVive Pharmaceutical AB, H1 2014
Type 2 Diabetes - Pipeline by Angelini Group, H1 2014
Type 2 Diabetes - Pipeline by Debiopharm International S.A., H1 2014
Type 2 Diabetes - Pipeline by Advinus Therapeutics Ltd., H1 2014
Type 2 Diabetes - Pipeline by CJ CheilJedang Corp., H1 2014
Type 2 Diabetes - Pipeline by Chipscreen Biosciences Ltd, H1 2014
Type 2 Diabetes - Pipeline by Aurigene Discovery Technologies Limited, H1 2014
Type 2 Diabetes - Pipeline by ActogeniX NV, H1 2014
Type 2 Diabetes - Pipeline by Camurus AB, H1 2014
Type 2 Diabetes - Pipeline by Jenrin Discovery, Inc., H1 2014
Type 2 Diabetes - Pipeline by reMYND, H1 2014
Type 2 Diabetes - Pipeline by Wellstat Therapeutics Corporation, H1 2014
Type 2 Diabetes - Pipeline by Celon Pharma Sp. z o.o., H1 2014
Type 2 Diabetes - Pipeline by Cortendo Invest AB, H1 2014
Type 2 Diabetes - Pipeline by Anchor Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Protemix Corporation Limited, H1 2014
Type 2 Diabetes - Pipeline by Allozyne, Inc., H1 2014
Type 2 Diabetes - Pipeline by Metabolic Solutions Development Co., H1 2014
Type 2 Diabetes - Pipeline by Zafgen Inc., H1 2014
Type 2 Diabetes - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Melior Discovery, Inc., H1 2014
Type 2 Diabetes - Pipeline by Diabetology Limited, H1 2014
Type 2 Diabetes - Pipeline by Braasch Biotech LLC, H1 2014
Type 2 Diabetes - Pipeline by Zealand Pharma A/S, H1 2014
Type 2 Diabetes - Pipeline by Intarcia Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Theracos, Inc., H1 2014
Type 2 Diabetes - Pipeline by Versartis, Inc., H1 2014
Type 2 Diabetes - Pipeline by Kainos Medicine, Inc., H1 2014
Type 2 Diabetes - Pipeline by Nordic Bioscience a/s, H1 2014
Type 2 Diabetes - Pipeline by InteKrin Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Virobay Inc., H1 2014
Type 2 Diabetes - Pipeline by Noxxon Pharma AG, H1 2014
Type 2 Diabetes - Pipeline by Avaxia Biologics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Intercept Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Omeros Corporation, H1 2014
Type 2 Diabetes - Pipeline by TransTech Pharma, Inc., H1 2014
Type 2 Diabetes - Pipeline by Bridge Bioresearch Plc, H1 2014
Type 2 Diabetes - Pipeline by Synthetic Biologics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Targacept, Inc., H1 2014
Type 2 Diabetes - Pipeline by N-Gene Research Laboratories, Inc., H1 2014
Type 2 Diabetes - Pipeline by Obio Pharmaceutical Holdings Limited, H1 2014
Type 2 Diabetes - Pipeline by ChemoCentryx, Inc., H1 2014
Type 2 Diabetes - Pipeline by USV Limited, H1 2014
Type 2 Diabetes - Pipeline by Vitae Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by CureDM, Inc., H1 2014
Type 2 Diabetes - Pipeline by Verva Pharmaceuticals Limited, H1 2014
Type 2 Diabetes - Pipeline by Exsulin Corporation, H1 2014
Type 2 Diabetes - Pipeline by Medestea Research & Production S.p.A., H1 2014
Type 2 Diabetes - Pipeline by NasVax Ltd., H1 2014
Type 2 Diabetes - Pipeline by Stelic Institute & Co., H1 2014
Type 2 Diabetes - Pipeline by Vybion, Inc., H1 2014
Type 2 Diabetes - Pipeline by Regulus Therapeutics Inc., H1 2014
Type 2 Diabetes - Pipeline by Esperion Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2014
Type 2 Diabetes - Pipeline by NGM Biopharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Alize Pharma SAS, H1 2014
Type 2 Diabetes - Pipeline by Ardelyx, Inc., H1 2014
Type 2 Diabetes - Pipeline by Heptares Therapeutics Ltd., H1 2014
Type 2 Diabetes - Pipeline by Mitsubishi Pharmaceutical Corporation, H1 2014
Type 2 Diabetes - Pipeline by Receptos, Inc., H1 2014
Type 2 Diabetes - Pipeline by MicroDose Therapeutx, Inc., H1 2014
Type 2 Diabetes - Pipeline by Sirona Biochem Corp, H1 2014
Type 2 Diabetes - Pipeline by XBiotech USA, Inc., H1 2014
Type 2 Diabetes - Pipeline by Carmot Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2014
Type 2 Diabetes - Pipeline by Serometrix, LLC, H1 2014
Type 2 Diabetes - Pipeline by PharmaIN Corporation, H1 2014
Type 2 Diabetes - Pipeline by Stempeutics Research Private Limited, H1 2014
Type 2 Diabetes - Pipeline by Serodus ASA, H1 2014
Type 2 Diabetes - Pipeline by SignPath Pharma Inc, H1 2014
Type 2 Diabetes - Pipeline by Elcelyx Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Thermalin Diabetes Inc., H1 2014
Type 2 Diabetes - Pipeline by Selvita S.A, H1 2014
Type 2 Diabetes - Pipeline by Poxel SA, H1 2014
Type 2 Diabetes - Pipeline by Medesis Pharma S.A., H1 2014
Type 2 Diabetes - Pipeline by Kadmon Pharmaceuticals, LLC, H1 2014
Type 2 Diabetes - Pipeline by Neopharm Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, H1 2014
Type 2 Diabetes - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014
Type 2 Diabetes - Pipeline by Metabolys S.A.S., H1 2014
Type 2 Diabetes - Pipeline by Boston Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Cardiolynx AG, H1 2014
Type 2 Diabetes - Pipeline by TWi Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Allinky Biopharma, H1 2014
Type 2 Diabetes - Pipeline by Rhizen Pharmaceuticals SA, H1 2014
Type 2 Diabetes - Pipeline by Hua Medicine Ltd., H1 2014
Type 2 Diabetes - Pipeline by Curaxys, S.L., H1 2014
Type 2 Diabetes - Pipeline by MidaSol Therapeutics LP, H1 2014
Type 2 Diabetes - Pipeline by Foresee Pharmaceuticals, LLC, H1 2014
Type 2 Diabetes - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2014
Type 2 Diabetes - Pipeline by CymaBay Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Biospherics.net Incorporated, H1 2014
Type 2 Diabetes - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014
Assessment by Monotherapy Products, H1 2014
Assessment by Combination Products, H1 2014
Number of Products by Stage and Target, H1 2014
Number of Products by Stage and Mechanism of Action, H1 2014
Number of Products by Stage and Route of Administration, H1 2014
Number of Products by Stage and Molecule Type, H1 2014
Type 2 Diabetes Therapeutics - Recent Pipeline Updates, H1 2014
Type 2 Diabetes - Dormant Projects, H1 2014
Type 2 Diabetes - Discontinued Products, H1 2014

List of Figures


Number of Products under Development for Type 2 Diabetes, H1 2014
Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Products, H1 2014
Assessment by Monotherapy Products, H1 2014
Assessment by Combination Products, H1 2014
Number of Products by Top 10 Target, H1 2014
Number of Products by Stage and Top 10 Target, H1 2014
Number of Products by Top 10 Mechanism of Action, H1 2014
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
Number of Products by Top 10 Route of Administration, H1 2014
Number of Products by Stage and Top 10 Route of Administration, H1 2014
Number of Products by Top 10 Molecule Type, H1 2014
Number of Products by Stage and Top 10 Molecule Type, H1 2014

Upcoming Reports:

Chronic Kidney Disease Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020
By - Transparency Market Research
Chronic kidney disease (CKD), which is also known as chronic renal disease, is caused due to progressive loss of proper functioning of the kidneys and associated renal system over a longer period of time either months or years. Chronic kidney diseases often go unnoticed, as the individuals suffering from the disease are seen to be having non-specific symptoms like feeling unwell, or loss of appetite among others. Many a times, patients suffering from a chronic kidney disorder are diagnosed due to their screening for diabetes, high blood pressure and others.  However, patients...
Polyhydroxyalkanoate Market - Global Industry Analysis, Market Size, Share, Trends, Analysis, Growth And Forecast, 2013 - 2019
By - Transparency Market Research
Polyhydroxyalkanoate (PHA) is biodegradable linear polyesters produced naturally by the chemical reaction of bacterial fermentation on lipids or sugar. PHAs can be combined with a wide array of monomers which results in the formation of different types of materials exhibiting a variety of properties. PHAs are used in several applications including packaging of food & beverages and cosmetics, bio-medical applications and agricultural films among others.  Rising demand for biodegradable materials owing to the rising awareness among consumers regarding environment protection...
Competitive Local Exchange Carriers (CLEC) Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020
By - Transparency Market Research
A telephone company which provides services such as telephone, fax, and other to a local area is known as local exchange carrier. Conventionally, in the U.S. prior to “Telecommunications Act 1996”, incumbent local exchange carriers (ILEC) offered calling services in a specific area. In order to enhance competition among the local phone and long-distance service providers, competitive local exchange carriers (CLEC) evolved. CLEC is a telephone company which operates in ILEC’s territory, offering the customers an alternative to the local phone service providers. CLECs are...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

New Drug Shows Early Promise against Heart Attacks and Strokes
Sep 1, 2014  
Sanofi and Regeneron Pharmaceuticals have been working on a new experimental drug that aims to lower cholesterol. Early tests have shown that the drug cuts down risks of heart attacks and strokes in clinical trials by half. The test report says that the results are not conclusive as the analysis was performed retrospectively. The study does provide the positive result that...
New Materials Creation Strategy
Sep 1, 2014  
Scientists always aim at theorizing about new compounds and materials; however after Researchers have made use of X-ray scattering in a process known as molecular beam epitaxy (MBE) to understand atom behavior as a kind of material called as layered oxides were getting formed. For computational predictions of new materials, the available observations were utilized for providing insights on...
Western Africa economies hit by Ebola travel ban
Aug 28, 2014  
With over 1,400 people dead due to the fatal Ebola outbreak in African countries, travel services have either banned or limited operations to the western region, severely hitting economies of the area. Budgetary resources are being utilized rapidly and economic growth has dropped by 4% as international projects and trips have been cancelled. Transport companies have cut off the region...
Fonterra Ties Up With Beingmate to Tap into China’s Baby Food Market
Aug 28, 2014  
Fonterra Co-Operative Group Ltd. will partner with Beingmate Group Co, China’s biggest infant formula manufacturer to increase its reach in the Chinese market. The New Zealand-based company makes this move with the intent to grab a bigger market share in China after it suffered many setbacks in the food-safety scandal last year.   This partnership will also help Beingmate...
Chinas Leading Asset-Management Company Aims for IPO
Aug 28, 2014  
China’s biggest asset-management company plans to go public by the end of 2015. Chinese authorities are constantly ramping up their interests towards introducing mixed ownership to state-owned huge companies and call for more private capital investments into the economy. According to the news report, China Huarong Asset Management Co., Ltd. will collaborate with eight investors...